Inflammatory breast carcinoma (IBC) is a rare but aggressive breast cancer (BC) subtype. General prognosis is poor with higher incidence of axillary node involvement and metastatic disease at presentation (~30 %) as compared with common BC (~10 %). The typical IBC is characterised by rapid onset of localised or generalised skin redness, involving at least one-third of the breast, warmth and usually presence of skin oedema (peau d'orange), often without an underlying tumour mass. This clinical presentation of skin inflammation is a consequence of pathological plugging of the dermal lymphatic of the breast with tumour emboli. Dermal lymphatic invasion (DLI), although not mandatory for IBC diagnosis, is one of the hallmarks of this malignancy and can be proven in up to 75-80 % of IBCs. Surprisingly, there are very few data regarding whether the presence of DLI independently contributes to IBC prognosis as compared with IBC without DLI.
Breast carcinoma (BC) is one of the commonest cancers in the world, and definitely the most common malignant disease in women with more than one million newly diagnosed patients each year.
However, among this common, but heterogeneous, malignancy, there is a subset of rare BC form called inflammatory breast carcinoma (IBC), representing approximately 1-5 % of all breast cancer types. 1 The term inflammatory was first proposed by Lee and Tannenbaum in 1924 , and this is still the most appropriate name for this form of breast carcinoma because it actually describes very accurately the typical clinical presentation. 2 
Clinical Presentation and Diagnosis
The hallmark of this rare BC type is rapid onset of localised or generalised typical skin redness, involving at least one-third of the breast, breast warmth and usually typical oedema (peau d'orange), often without an underlying tumour mass.
Although this specific form of BC was first recognised long ago, diagnostic criteria were inconsistent and IBC had been often grouped with locally advanced breast cancer (LABC), especially if accompanied with secondary inflammation (see Figure 1 ). This inconsistency was leading to a discrepancy in incidence reporting, especially in some parts of the world. 2 For instance, the first reports about rapidly developing BC from Tunisia stated high IBC incidence exceeding 50 % of patients with BC, provoking speculation that some unidentified environmental factors could contribute to IBC development. 3 However, later reports using more standardised criteria showed significantly lesser incidence and the cause of IBC still remained elusive. 4 After separate guidelines for the work-up and treatment of patients with IBC were finally developed and published in 2008, fewer patients with IBC are misdiagnosed for LABC because major clinical and pathological characteristics have become widely known. 5 Today it is well established that IBC represents a completely distinct clinical entity, different from LABC, with different clinical and pathology presentation and molecular characteristics, as well as treatment outcome and prognosis. 6 The clinical presentation of IBC is usually impressive, with rapidly developed skin redness, oedema and breast enlargement (see Figure  2 and 12 Major molecular characteristics are also defined and it is known that up to 83 % of IBC tumours lack oestrogen receptor (ER) expression, while HER2 overexpression is significantly higher than in non-IBC patients. [13] [14] [15] [16] [17] [18] However, an International IBC Panelist recently stated that the true prognostic significance of HER2 overexpression among women with IBC is currently still unknown, in contrast to the well-known negative prognostic impact that HER2 overexpression has in common BC.
interfere with HER2 expression's well-known predictive significance to trastuzumab treatment, and all IBC patients with HER2 overexpression should be treated with trastuzumab.
Impact of Dermal Lymphatic Invasion on the Prognosis of Inflammatory Breast Carcinoma
Historically, clinical presentation that resembles non-malignant acute mastitis was the main reason for delay in diagnosis and treatment in many patients. However, this typical clinical presentation of breast skin inflammation is not due to true physiological inflammatory response but is rather a consequence of pathological plugging of the dermal lymphatic of the breast with tumour emboli.
This pathological phenomenon was observed long ago, when Thomas
Bryant in 1887 observed pathological tumour invasion of the dermal lymphatic vessels, recognising that lymphatic obstruction produced the clinical appearance of inflammation. 23 Later, IBC was determined as a clinical entity in which confirmation of dermal lymphatic invasion (DLI) is equivalent to 'pathological proof' of this rare malignancy, because it is caused by filling of the dilated dermal lymphatics by tumour emboli, subsequently leading to lymphatic obstruction and producing the typical inflammatory appearance. 24 This was so convincing as a dominant pathology event for many researchers that they preferred the pathological over the clinical definition for IBC, proposing "dermal lymphatic carcinomatosis of the breast" as the alternative phrase instead of inflammatory breast carcinoma. 25, 26 However, it was soon recognised that even with an adequate number However, skin involvement in IBC is technically always interpreted as a metastatic site at the time of primary diagnosis. Therefore, it could be expected that proven skin involvement actually represents the most important factor for generally poorer prognosis of patients with IBC. In fact, it has been proposed that DLI is responsible for the high metastatic potential of IBC. Inflammatory Breast Cancer survival in ~20 % of patients was reported. 8, 19 However, to the best of our knowledge, these studies have not explored whether there are differences in treatment outcomes according to the presence or absence of DLI in IBC.
In the literature review, we have found only a few studies specifically addressing the significance of DLI in IBC prognosis.
In one small study authors explored whether tumour emboli in dermal lymphatics without inflammatory signs represent a similar bad prognosis like with classical inflammatory breast cancer. In that small study, the presence or absence of ID was the only significant parameter for all end-points in multivariate analyses.
Despite the same histopathologic presentation, DLI without ID was accompanied by significantly better DFS and OS than ID.
In a larger study, the outcome of 163 IBC patients with or without DLI was compared with the outcome of 99 patients with proven DLI but without an inflammatory component. 35 Individual patient prognosis with IBC still cannot be predicted, except that better outcome could be expected in those who obtain pathological complete response after chemotherapy. 19 For most patients, the statement from previous studies that IBC could be defined either clinically or pathologically, but the prognosis would be poor either way, still stands. 28,38 n Breast Cancer
